Bayforest Capital’s Intellia Therapeutics NTLA Stock Holding History

Bayforest Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.3K	Sell	1,351 -6,052	-82%	-$75.7K	0.02%	716
2026 Q2	$125K	Buy	7,403 +1,033	+16%	+$14.5K	0.12%	350
2026 Q1	$81.7K	Buy	+6,370	New	+$81.1K	0.09%	423
2025 Q4	–	Sell	-262	Closed	-$4.52K	–	903
2025 Q3	$4.52K	Buy	+262	New	+$3.23K	﹤0.01%	698
2025 Q1	–	Sell	-2,496	Closed	-$29.1K	–	846
2024 Q4	$29.1K	Buy	+2,496	New	+$39K	0.04%	540

Other funds holding NTLA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bayforest Capital's NTLA Position: Q3 2026 in Review

Bayforest Capital reduced its Intellia Therapeutics (NTLA) stake by 82% in Q3 2026, selling an estimated $75.7K and leaving 1,351 shares worth $16.3K. The position accounts for 0.02% of the portfolio, ranked #716.

Bayforest Capital first reported a position in NTLA in Q4 2024 and has held it in 5 quarters since. The position peaked at $125K in Q2 2026. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

Bayforest Capital held 1,351 shares of Intellia Therapeutics worth $16.3K as of Q3 2026.
Bayforest Capital sold 6,052 Intellia Therapeutics shares in Q3 2026, an estimated $75.7K.
Intellia Therapeutics made up 0.02% of Bayforest Capital's portfolio in Q3 2026, its #716 holding.
Bayforest Capital first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 5 quarters since.
Bayforest Capital's Intellia Therapeutics position peaked at $125K in Q2 2026.
239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Bayforest Capital's 13F filing for Q3 2026, filed 3 Nov 2026.